Drug Approval | March 16, 2024
Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility
The company is confident of addressing the concern raised by the USFDA
The company is confident of addressing the concern raised by the USFDA
Sen spent a decade with Biocon and held various key roles,
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Women emerge as the cornerstone of this monumental undertaking
Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function
The inspection was concluded with few procedural observations
The company will provide comprehensive response to USFDA for the observations
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Subscribe To Our Newsletter & Stay Updated
